Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Corcept Therapeutics (CORT)

Corcept Therapeutics (CORT)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,391,574
  • Shares Outstanding, K 115,927
  • Annual Sales, $ 353,870 K
  • Annual Income, $ 106,010 K
  • 60-Month Beta 0.69
  • Price/Sales 6.69
  • Price/Cash Flow 22.83
  • Price/Book 4.78
Trade CORT with:

Options Overview

Details
  • Implied Volatility 35.11%
  • Historical Volatility 16.10%
  • IV Percentile 2%
  • IV Rank 1.72%
  • IV High 208.16% on 11/12/20
  • IV Low 32.08% on 09/01/21
  • Put/Call Vol Ratio 28.00
  • Today's Volume 116
  • Volume Avg (30-Day) 143
  • Put/Call OI Ratio 26.00
  • Today's Open Interest 351
  • Open Int (30-Day) 1,095

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/21
See More
  • Average Estimate 0.19
  • Number of Estimates 3
  • High Estimate 0.21
  • Low Estimate 0.18
  • Prior Year 0.17
  • Growth Rate Est. (year over year) +11.76%

Price Performance

See More
Period Period Low Period High Performance
1-Month
19.91 +3.01%
on 09/17/21
21.83 -6.05%
on 09/03/21
+0.06 (+0.29%)
since 08/17/21
3-Month
19.63 +4.48%
on 07/28/21
23.14 -11.37%
on 06/21/21
-2.48 (-10.79%)
since 06/17/21
52-Week
16.42 +24.91%
on 09/24/20
31.18 -34.22%
on 02/09/21
+3.30 (+19.14%)
since 09/17/20

Most Recent Stories

More News
Positive Results Presented at ESMO 2021 From Randomized, Controlled, Phase 2 Trial of Relacorilant in Patients with Recurrent Platinum-Resistant Ovarian Cancer

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating...

CORT : 20.51 (-0.58%)
Corcept Announces Presentation of Positive Results From Randomized, Controlled, Phase 2 Trial of Relacorilant in Patients With Recurrent Platinum-Resistant Ovarian Cancer at ESMO 2021

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating...

CORT : 20.51 (-0.58%)
SHAREHOLDER ALERT: Morris Kandinov Investigating ODT, AYTU, EAR, and CORT; Shareholders are Encouraged to Contact the Firm

National law firm Morris Kandinov is investigating the actions of the officers and board of directors of Odonate Therapeutics, Inc., Aytu Biopharma, Inc., Eargo, Inc., and Corcept Therapeutics, Inc. ...

ODT : 3.00 (-6.54%)
AYTU : 3.13 (+3.30%)
EAR : 21.97 (+0.92%)
CORT : 20.51 (-0.58%)
William Guyer to join Corcept as Chief Development Officer

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating...

GILD : 71.61 (+0.39%)
CORT : 20.51 (-0.58%)
Corcept's (CORT) Q2 Earnings Beat Estimates, Revenues Rise Y/Y

Corcept (CORT) beats on both earnings and revenues in the second quarter of 2021. The company maintains the revenue guidance for 2021.

BMY : 61.31 (+0.13%)
PFE : 43.89 (-1.30%)
MRK : 71.68 (-0.40%)
CORT : 20.51 (-0.58%)
Corcept Therapeutics (CORT) Q2 Earnings and Revenues Surpass Estimates

Corcept (CORT) delivered earnings and revenue surprises of 50.00% and 6.72%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

CORT : 20.51 (-0.58%)
Corcept: Q2 Earnings Snapshot

MENLO PARK, Calif. (AP) _ Corcept Therapeutics Inc. (CORT) on Thursday reported second-quarter profit of $26.5 million.

CORT : 20.51 (-0.58%)
Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and neuropsychiatric disorders by modulating...

CORT : 20.51 (-0.58%)
Dr. Reddy's (RDY) Q1 Earnings Decline Y/Y, Sales Increase

Dr. Reddy's (RDY) earnings decline while sales grow year over year in first-quarter fiscal 2022.

RDY : 66.35 (-0.85%)
RGEN : 306.90 (+2.34%)
CORT : 20.51 (-0.58%)
NBRV : 1.1500 (unch)
CORT or ZTS: Which Is the Better Value Stock Right Now?

CORT vs. ZTS: Which Stock Is the Better Value Option?

CORT : 20.51 (-0.58%)
ZTS : 198.49 (-2.11%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Corcept Therapeutics Incorporated is a pharmaceutical company. It is engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. The company focuses on disorders that are associated with a steroid hormone called cortisol....

See More

Key Turning Points

3rd Resistance Point 21.36
2nd Resistance Point 20.95
1st Resistance Point 20.73
Last Price 20.51
1st Support Level 20.10
2nd Support Level 19.69
3rd Support Level 19.47

See More

52-Week High 31.18
Fibonacci 61.8% 25.54
Fibonacci 50% 23.80
Fibonacci 38.2% 22.06
Last Price 20.51
52-Week Low 16.42

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar